Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat glaucoma and other serious diseases of the eye.
Use the links above to view videos of our key leaders and contributors discussing Inotek's mission, vision, and the potential therapeutic value of our lead product candidate, trabodenoson.
Inotek recognizes World Glaucoma Week March 12-18 and stands with the glaucoma community in striving to halt the second leading cause of blindness. Please visit http://www.wgweek.net/about-world-glaucoma-week/ for more information.
Adenosine is an important molecule occurring naturally in the body that participates in a wide variety of physiological and pathological processes. Inotek’s scientists have deconstructed adenosine’s complex biology to isolate the protective activity of the molecule, and subsequently to build it into novel therapeutics.Read More >
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar. 16, 2017-- Inotek Pharmaceuticals Corporation (NASDAQ:ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today reported financial results and operational highlights for the fiscal year ended December 31, 2016. “In 2016, Inotek completed the Phase 3 MATrX-1 clinical trial of trabodenoson...Read More >